Insider sale details
Tomas Navratil, Glaukos Corporation's Chief Development Officer, disposed of 1,031 shares of the company's common stock on March 16, 2026, receiving approximately $101,078 in aggregate. The transactions occurred at prices between $97.33 and $99.05 per share. Concurrently, the issuer withheld 958 shares from Navratil to satisfy tax obligations associated with the vesting of restricted stock units; those withheld shares covered $94,784 at a withholding price of $98.94.
Following these actions, Navratil's direct holdings in Glaukos total 73,631 shares, a figure that includes 35,687 restricted stock units that have not yet vested. The dispositions were carried out pursuant to a Rule 10b5-1 trading plan that Navratil adopted on March 12, 2026.
Market context and company financials
At the time of reporting the shares trade at $102.09, reflecting a market capitalization of $5.92 billion. The company has not produced a profit over the trailing twelve months. According to an InvestingPro analysis cited in company coverage, the stock appears overvalued at current price levels. The same coverage notes that 10 analysts have recently revised earnings estimates downward.
Regulatory development: iDose TR labeling supplement approved
Glaukos announced that it received Food and Drug Administration approval for its new drug application (NDA) labeling supplement permitting repeat administration of the iDose TR product. The approval allows physicians to re-administer the implant using a repeat treatment protocol in patients with healthy corneas, expanding the therapeutic options for glaucoma management.
Analyst reactions and guidance notes
Market reaction from equity research teams has been supportive following the regulatory update. BTIG raised its price target on Glaukos to $131 from $123 and maintained a Buy rating. Needham increased its target to $127 from $125 and likewise kept a Buy rating, noting that Glaukos' fourth-quarter 2025 revenue was consistent with its preannouncement and that the company reiterated its 2026 revenue guidance.
Stifel reiterated a Buy rating and a $160 price target, highlighting what it described as an attractive risk-reward profile for the iDose product despite the possibility of local coverage determination (LCD) restrictions. Stifel also noted that Glaukos expects sequential iDose growth in 2026 after a slowdown in the fourth quarter of 2025 and conducted a survey to assess near-term catalysts for the product. Both Stifel and Needham emphasized growing momentum for Glaukos' iDose and Epioxa offerings.
What this means for investors
The insider sale was executed through a pre-arranged plan and included tax-withholding activity tied to RSU vesting. The company received a regulatory nod that broadens clinical application of iDose TR and prompted several firms to lift price targets while maintaining Buy ratings. At the same time, Glaukos remains unprofitable on a trailing-twelve-month basis and has experienced downward analyst earnings revisions.
Investors assessing Glaukos will need to weigh the newly broadened treatment pathway for iDose TR and supportive analyst commentary against persistent unprofitability and recent earnings estimate reductions.